Combination of interferon with tyrosine kinase inhibitor
Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.
VIDEOS
Dr. Hochhaus on TFS With Nilotinib in Patients With CML
June 3, 2016, OncLiveTV
Prof Andreas Hochhaus: Welt-CML-Tag und TIGER-Studie
October 4, 2012, Jan Geissler
Dr. Hochhaus on TFS With Nilotinib in Patients With CML
June 3, 2016, OncLiveTV
Prof Andreas Hochhaus: Welt-CML-Tag und TIGER-Studie
October 4, 2012, Jan Geissler
CLINICAL TRIALS
Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response
April 9, 2018, Australian New Zealand Clinical Trials Registry
Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER)
August 22, 2017, ClinicalTrials.gov
Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response
April 9, 2018, Australian New Zealand Clinical Trials Registry
Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER)
August 22, 2017, ClinicalTrials.gov
ARTICLES
Nordic clinical trial opens the door to a cure for a blood cancer
September 21, 2022, Helsinki Times
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
September 1, 2022, JCI
Peg-Interferon Αlpha 2b can improve molecular recurrences in the TREATMENT-FREE REMISSION; A pilot study with 18-month follow-up
June 2018, EHA 2018
Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study
2017, ASH2017
Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial
2017, ASH2017
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
February 25, 2015, Leukemia
Tyrosine Kinase Inhibitors and Interferon
January 2 , 2014, NCBI
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
December 14, 2012, Leukemia
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
December 23, 2010, The New England Journal of Medicine
Nordic clinical trial opens the door to a cure for a blood cancer
September 21, 2022, Helsinki Times
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
September 1, 2022, JCI
Peg-Interferon Αlpha 2b can improve molecular recurrences in the TREATMENT-FREE REMISSION; A pilot study with 18-month follow-up
June 2018, EHA 2018
Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study
2017, ASH2017
Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial
2017, ASH2017
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
February 25, 2015, Leukemia
Tyrosine Kinase Inhibitors and Interferon
January 2 , 2014, NCBI
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
December 14, 2012, Leukemia
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
December 23, 2010, The New England Journal of Medicine
